Grace Therapeutics, Inc. (GRCE) Stock

NASDAQ: GRCEHealthcare company in the biotechnology industry, based in Princeton, NJ.

Grace Therapeutics stock price chart

GRCE interactive chart →

GRCE stock quote & key statistics

Grace Therapeutics earnings per share

Income →
Earnings per share

Grace Therapeutics revenue & net income

Income →
RevenueNet income

Grace Therapeutics annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2026$0-$7.8M-$0.64
FY2025$0-$13.6M-$1.21
FY2024$0-$17.4M-$1.43
FY2023$0-$57.4M-$1.58
FY2022$0-$12.3M-$1.11

Fiscal year ending March 31. Source: company filings via EODHD.

About Grace Therapeutics, Inc.

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN).

The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Grace Therapeutics stock FAQ

What is the Grace Therapeutics stock ticker symbol?

Grace Therapeutics, Inc. trades on the NASDAQ under the ticker symbol GRCE.

What sector and industry is Grace Therapeutics in?

Grace Therapeutics, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Grace Therapeutics have?

Grace Therapeutics, Inc. has about 5 full-time employees.

What were Grace Therapeutics's revenue and earnings last fiscal year?

Grace Therapeutics reported revenue of $0 and net income of -$7.8M in fiscal 2026, with earnings per share of -$0.64.

When did Grace Therapeutics go public?

Grace Therapeutics stock began trading on October 8, 2024.

Biotechnology stocks

All Healthcare stocks →